Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma
Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04812145
Collaborator
(none)
50
24
Study Details
Study Description
Brief Summary
Estimate the response to modified hypofractionated radiotherapy concurrent with Gemcitabine in urinary bladder cancer patients .
Estimate local control, relapse free survival, overall survival and bladder preservation rate. Evaluate the toxicity of a modified hypofractionated chemoradiotherapy protocol for patients with invasive bladder cancer.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
50 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma
Anticipated Study Start Date
:
Apr 1, 2021
Anticipated Primary Completion Date
:
Jan 1, 2023
Anticipated Study Completion Date
:
Apr 1, 2023
Outcome Measures
Primary Outcome Measures
- Response to hypofractionated radiotherapy concurrent with Gemcitabine in urinary bladder cancer [baseline]
Estimate Disease free survival .
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- Pathologically confirmation of transitional cell carcinoma . Non metastatic invasive bladder cancer (TNM0) Any age group ≥ 18 years. Non pregnant female patients.
Exclusion Criteria:
- Other pathology than Transitional cell carcinoma Metastatic Patient Age less than 18 years
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Assiut University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
Responsible Party:
Esraa Mostafa Abdelzaher Mohamed,
Principal Investigator,
Assiut University
ClinicalTrials.gov Identifier:
NCT04812145
Other Study ID Numbers:
- U.Bladder Cancer Radiotherapy
First Posted:
Mar 23, 2021
Last Update Posted:
Mar 23, 2021
Last Verified:
Mar 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: